| Cat. No. |
Size |
Price |
Figures |
|---|
RP11670-1 mg
| 1 mg | $ 171.00 | MSDS: 20080919024136 (PDF)
References:
- Pause A, et al. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J. Biol. Chem. May 2003; 278(22): 20374-20380.
- Kai Lin, et al. Combination of a Hepatitis C Virus NS3-NS4A Protease Inhibitor and Alpha Interferon Synergistically Inhibits Viral RNA Replication and Facilitates Viral RNA Clearance in Replicon Cells. Antimicrob Agents Chemother. Dec 2004; 48(12): 4784–4792.
|
|---|
RP11670-5 mg
| 5 mg | $ 513.00 |
|---|
| Full Name | | Hepatitis C Virus NS3 Protease Inhibitor 1 |
|
Sequence
(one-letter code) |
Ac-DEMEEC |
Sequence
(three-letter code) | {ASP}{GLU}{MET}{GLU}{GLU}{CYS} |
|---|
| Description | Hepatitis Virus C NS3 Protease Inhibitor 1 is a potent peptide inhibitor of hepatitis virus C NS3 protease. The hepatitis C virus (HCV) NS3 protease is essential for polyprotein maturation and viral propagation, and it has been proposed as a suitable target for antiviral drug discovery. An N-terminal hexapeptide cleavage product of a dodecapeptide substrate identified as a weak competitive inhibitor of the NS3 protease activity was optimized to a potent and highly specific inhibitor of the enzyme. The effect of this potent NS3 protease inhibitor was evaluated on replication of subgenomic HCV RNA and compared with interferon- (IFN-), which is currently used in the treatment of HCV-infected patients. |
|---|
| Formula | C29H44N6O16S2 |
|---|
| M.W. | 796.82 |
|---|
| Purity | > 95% |
|---|
| Storage | Store the peptide at -20°C. |
| N-Terminal | AC |
|---|
